Saturday 17 October 2026
Export BLTE’s income statement to Excel — free account
Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 40.0% and free cash flow grew 64.7%, each against the same quarter a year earlier.
142.78
9.84
−6.45%
Follow BLTE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(37.83%) | (18.85%) | 0.00% | 0.00% | |
| (31.33%) | (16.64%) | (18.51%) | (21.60%) | ||
ROIC |
0.00% | (18.93%) | (7.96%) | (9.55%) | |
Return on Tangible Assets |
(23.15%) | (16.02%) | (17.83%) | (21.03%) | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(2.58) | (1.99) | 0.00 | 0.00 | |
Free Cash Flow |
(85.67) | (66.58) | — | — | |
Capital Expenditures |
— | (0.36) | — | — | |
| Other line items | |||||
Cash ROIC |
(15.59%) | (5.27%) | 0.00% | 0.00% | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | |
Operating CF/Net income |
1.37 | 0.85 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
3.77 | 2.65 | — | — | |
Capex/Depreciation |
0.00 | (0.39) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.58) | (1.97) | 0.00 | 0.00 | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates